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Abstract
Background Thereislackofvalidationandstandardisationof
acquisition parameters for myocardial
123I-metaiodobenzyl-
guanidine (MIBG). This lack of standardisation hampers
large scale implementation of
123I-MIBG parameters in the
evaluation of patients with chronic heart failure (CHF).
Methods In a retrospective multi-centre study
123I-MIBG
planar scintigrams obtained on 290 CHF patients (82%
male; 58% dilated cardiomyopathy; New York Heart
Association [NYHA classification] > I) were reanalysed to
determine the late heart-to-mediastinum ratio (H/M).
Results There was a large variation in acquisition parameters.
Multivariate forward stepwise regression showed that a
significant proportion (31%, p<0.001) of the variation in
late H/M could be explained by a model containing patient-
related variables and acquisition parameters. Left ventricular
ejection fraction (p<0.001), type of collimation (p<0.001),
acquisition duration (p=0.001), NYHA class (p=0.028) and
age (p=0.034) were independent predictors of late H/M.
Conclusions Acquisitions parameters are independent con-
tributors to the variation of semi-quantitative measurements
of cardiac
123I-MIBG uptake. Improved standardisation of
cardiac
123I-MIBG imaging parameters would contribute to
increased clinical applicability for this procedure.
Keywords Heartfailure.Instrumentation.MIBG.
Prognosis
Introduction
Radiolabelled metaiodobenzylguanidine (
123I-MIBG), an
analog of the false neurotransmitter guanethidine, localises
inadrenergic nerve terminals primarilyvia the norepinephrine
(NE) transporter (uptake-1) system [1, 2]. In the past two
decades, a large number of investigators have demon-
strated decreased myocardial
123I-MIBG uptake in heart
failure patients and have shown that those with the lowest
uptake tend to have the poorest prognosis [3–11]. There
have also been findings suggesting that abnormalities of
myocardial
123I-MIBG uptake may be predictive of
increased risk for ventricular arrhythmia and sudden
cardiac death (SCD) [12, 13].
One factor that has constrained acceptance of cardiac
123I-MIBG imaging as a clinical patient management tool in
heart failure has been the variability of technical aspects of
the procedure. Although most publications have included
the heart-to-mediastinum ratio (H/M) as the measure of
myocardial uptake, the methods used to obtain this
parameter show considerable variation. In addition, the
influence of procedural and acquisition parameters on the
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occasionally been considered. While the effect of collimator
selection on H/M ratios has been studied, similar attention
has not been paid to the impact of administered activity,
acquisition time and duration [14]. Given the absence of
published guidelines for cardiac
123I-MIBG imaging, stand-
ardisation of procedures among individual users of this
agent becomes even more important.
The objective of the present study was to examine the
influence of procedural variables associated with
123I-
MIBG imaging when a standardised technique was used
to determine the H/M ratio.
Materials and methods
Study design
Myocardial
123I-MIBG scintigrams on 290 heart failure
patients (male and female subjects ≥18 years of age with
New York Heart Association [NYHA] Classes II–IV) from
six sites in five European countries were retrieved and
analysed. These imaging studies were performed between
1993 and 2002 and were collected for a previously
described trial [15]. This trial was designed to show that
standardised methodology could be applied to the analysis
and processing of
123I-MIBG myocardial images to obtain
reproducible quantitative results. As the large majority of
patients had only late planar
123I-MIBG images, the
analysis of these images is the sole focus of this paper.
Investigational sites sent copies of all digital image files
to an Imaging Core Laboratory (ICL) for evaluation and
analysis. Data on amount of
123I-MIBG activity injected
and image acquisition parameters (i.e. delay after injection
of
123I-MIBG and start of acquisition, acquisition duration
and type of collimator used) were collected.
The primary efficacy objective of the original trial was to
determine the prognostic significance of the late H/M ratio in
relation to occurrence of major cardiac events (MCE), defined
as either: 1) cardiac death due to all causes, including
myocardial infarction (MI), progressive heart failure and
sudden cardiac death (SCD); 2) cardiac transplant; 3) poten-
tially fatal arrhythmic event, including resuscitated cardiac
arrest or appropriate internal cardiac defibrillator (ICD)
discharge. Results of that analysis have been published. For
the purposes of this paper, H/M thresholds associated with
low-, intermediate- and high-risk for MCEs were defined to
provide the basis for the multivariate analysis described below.
Image analysis
An experienced nuclear medicine technologist not affiliated
with the ICL processed all the planar images to determine
the heart/mediastinum (H/M) ratio. The heart region of
interest (ROI) was drawn manually to include both
ventricles and any atrial activity that was clearly visible.
A square mediastinal ROI was drawn in the upper
mediastium, using the apices of the lungs as anatomic
landmarks (Fig. 1). The H/M ratio was calculated as the
ratio of the counts/pixel in the two ROIs.
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Fig. 1 Example of processing
procedure for late planar
123I-MIBG images. The posi-
tioning of the mediastinal ROI
was standardized in relation to
the lung apex, the lower bound-
ary of the upper mediastinum
and the midline between the
lungs
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Data are presented as mean ± standard deviation, unless
indicated otherwise. Kaplan–Meier survival analysis and
the log-rank test were used to analyse differences in event
rate for different subject groups defined by the late H/M
thresholds. Differences between these groups for continu-
ous data were compared using analysis of variance
(ANOVA) with a post hoc Bonferroni. Categorical data
were compared using the Fisher’s exact test. A forward
stepwise multivariate regression analysis was performed to
determine independent predictors of late H/M. Explanatory
variables were related to patient characteristics (i.e. gender,
age, NYHA class, left ventricular ejection fraction [LVEF],
and underlying etiology of heart failure) and to acquisition
parameters (i.e. amount of injected
123I-MIBG activity,
collimator type, delay after injection and start of acquisi-
tion, and duration of acquisition). Multivariate forward
stepwise regression analysis was performed for all study
subjects. The overall goodness-of-fit for each model was
expressed as the adjusted R
2. The F test was used to assess
whether a model explained a significant proportion of the
variability. A p<0.05 was considered to indicate a
statistically significant difference. All statistical analyses
were performed with SPSS (SPSS for Windows, version
11.01, SPSS Inc, Chicago, IL, USA).
Results
As previously described, there were 67 major cardiac events.
Figure 2 shows a Kaplan–Meier survival analysis for three
different groups of late H/M. Quantitative estimates for low
risk (late H/M >2.0, 2-year survival of 95%), intermediate
risk (late H/M 1.4–2.0, 2-year survival of 76%) and high risk
(late H/M <1.4, 2-year survival of 45%) could be deter-
mined. The differences in event rate were statistically
significant between the three groups (all p<0.001).
Table 1 shows the baseline characteristics and the
parameters related to the
123I-MIBG acquisition of all
subjects and for the three different groups of late H/M.
Overall, the majority of subjects were male and were in
functional class II according the NYHA classification and
had a LVEF<50% (n=262). Between the three late H/M
groups, there were differences in age (subjects with a late
H/M >2.0 were younger), NYHA classification, LVEF
(increasing from subjects with a late H/M <1.4 to subjects
witha late H/M>2.0) and HF etiology. In addition, there were
no differences in parameters of heart failure (LVEF and
NYHA classification) between the different centres.
Overall, most acquisitions were performed with low-
energy high-resolution (LEHR) collimators (74%), fol-
lowed by low-energy general purpose (LEGP) collimators
(17%). Only 9% of acquisitions were made with medium-
energy (ME) collimators, all from one centre. The amount
of activity injected ranged from 72 to 370 MBq (mean 164±
53 MBq). There was a large variation in the time-span after
between injection of
123I-MIBG and imaging, ranging from
1.9 up to 6.9 h (mean delay 4.3±0.6 h). The duration of
acquisition could be classified in seven categories: 1, 2, 3,
4, 5, 10 and 15 min. The majority of acquisitions was
performed with a 10-min duration (n=203). There were
differences between the three late H/M groups in collimator
type, amount of injected
123I-MIBG, delay after injection,
and duration of acquisition (Table 1).
Table 2 shows the results of the stepwise multivariate
regression analysis for all subjects and all parameters.
LVEF, collimator type, duration of acquisition, NYHA
classification and age were independent predictors of late
H/M. This model predicted approximately 30% of the
variation in late H/M results (p<0.0001). Even after
exclusion of the very low acquisition durations (<5 min),
the duration of acquisition remained an independent
predictor of late H/M.
In subjects with a late H/M <1.4, stepwise multivariate
regression analysis showed that NYHA classification and
delay after injection were the only independent predictors
of late H/M (Table 3). This model predicted approximately
10% of late H/M (p=0.03). In subjects with a late H/M 1.4–
2.0, stepwise multivariate regression analysis showed that
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Fig. 2 Kaplan–Meier curve showing the relation between survival and
time to first major cardiac event for three groups with different H/M
values: late H/M <1.4 vs late H/M 1.4–2.0, p<0.0001; late H/M<1.4 vs
late H/M >2.0, p<0.0001; late H/M 1.4–2.0 vs late H/M>2.0, p<0.0001
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predictors of late H/M (Table 4). This model predicted
approximately 10% of late H/M (p=0.001). In subjects with
a late H/M >2.0, duration of acquisition was the only
independent predictor of late H/M (Table 5). However,
duration of acquisition predicted only 1% of late H/M and
explained a statistically non-significant proportion of
variability (p=0.347).
Discussion
In a heterogeneous population of heart failure patients, the
most important determinant of cardiac uptake of
123I-MIBG
is the degree of impairment of the NE transporter function
in presynaptic adrenergic neurons [3–11]. As such, consid-
erable variation in late H/M would be expected between
patients with otherwise similar clinical presentations
(NYHA class, LVEF, etc). Nevertheless, the findings of
the present study indicate that a proportion of the variation
in the late H/M
123I-MIBG can also be explained by
differences in acquisition parameters. Of particular interest,
the factors contributing to this variation differed for
different ranges of late H/M.
Abnormalities in myocardial
123I-MIBG imaging have
been demonstrated in patients with both common cardiac
pathologies such as CAD, CHF, and non-ischemic cardio-
myopathy [3–12, 16–18] and more uncommon entities such
as Syndrome X [19], Brugada Syndrome [20] and idio-
pathic ventricular fibrillation [13]. However, there has been
limited standardisation of the acquisition and quantitative
analysis techniques used by various investigators, and most
studies have involved small numbers of subjects and locally
defined reference standards and measures of outcome.
Thus, despite the large number of studies on cardiac
123I-
MIBG imaging, these methodological and analytical limi-
tations have hampered the implementation of this technique
for the evaluation and management of individual patients.
Acquisition duration was one of the independent
predictors of late H/M. The positive correlation suggests
that a longer acquisition time is associated with a higher
Table 2 Multivariate analysis of clinical and acquisition related
parameters as predictors of late H/M for all subjects (N=290)
Variables Coefficient b Standard error bP value
Constant 0.549 0.411
LVEF 0.015 0.02 <0.001
Collimator type 0.531 0.087 <0.001
Duration of
acquisition
0.045 0.014 0.001
NYHA −0.121 0.055 0.028
Age −0.006 0.003 0.034
Goodness-of-fit of the model: adjusted R
2 =0.312; P value=<0.0001
Table 3 Multivariate analysis of clinical and acquisition related
parameters as predictors of late H/M for subjects with a late H/M<1.4
(N=51)
Variables Coefficient b Standard error bP value
Constant 1.680 0.161
NYHA −0.055 0.027 0.049
Delay after injection −0.068 0.030 0.031
Goodness-of-fit of the model: adjusted R
2 =0.104; P value=0.030
Table 1 Patient and scintigraphic parameters for all subjects and subdivided by late H/M
123I-MIBG
All (N=290) Late H/M
<1.4 (N=51) 1.4–2.0 (N=143) >2.0 (N=96)
Patient characteristics
Male/Female 237/53 39/12* 117/26* 81/15*
Age (years) 53±11 (21–83) 55±10‡ 54±10‡ 49±11
NYHA (II/III/IV) 165/116/9 11/34/6† 85/55/3† 69/27/0†
LVEF (%) 32±14 (7–85) 23±9† 31±13‡ 39±14*
Etiology of heart failure (isch/non-isch) 121/169 20/31‡ 70/73‡ 31/65‡
Scintigraphic parameters
Collimator type (LEGP/LEHR/ME) 50/216/24† 24/25/2† 24/104/15† 2/87/7†
Activity (MBq) 164±53 (72–370) 145±31† 173±64 160±41
Delay after injection (h) 4.3±0.6 (1.9–6.9) 4.1±0.5‡ 4.3±0.5‡ 4.5±0.6
Duration of acquisition (min) 9.6±3.3 (1–15) 11.3±4.3† 9.2±3.4 9.4±2.0*
Data are presented as mean ± standard deviation (range).
NYHA New York Heart Association, LVEF left ventricular ejection fraction, Isch ischemic, Non-isch non-ischemic, LEGP low-energy all purpose,
LEHR low-energy high resolution, ME medium energy, MBq mega-Becquerel, h hours, min minutes.
Categorical data (Fisher’s exact test, for each group): *p=0.53; †p<0.001; ‡p<0.035.
Continuous data (ANOVA with posthoc Bonferoni): *p<0.01 compared to late H/M <1.4; †p<0.01 compared to late H/M 1.4–2.0; ‡p<0.01
compared to late H/M >2.0.
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reflects that a longer acquisition time results in a higher
number of counts and the allied improvement of count
statistics. In particular, in patients with reduced myocardial
uptake (i.e. heart failure patients), the higher signal-to-noise
ratio for a longer acquisition (≥10 min in the present study)
plays a pivotal role in the accurate assessment of late H/M.
In addition, delay after injection was in high-risk subjects
(late H/M <1.4), an independent predictor of late H/M. The
negative correlation suggests that a longer acquisition time
is associated with a lower late H/M.
However, in analogy to acquisition duration, it is more
likely that this association reflects that a longer delay results
in a lower number of counts and the allied deterioration of
count statistics. In particular, in patients with reduced
myocardial uptake (i.e. heart failure patients), the higher
signal-to-noise ratio for a shorter delay after injection plays
a pivotal role in the accurate assessment of late H/M.
Themostwell-validatedinfluenceonthemeasuredlateH/
M is the collimator type. Because of the high-energyphotons
emitted by
123I, septal penetration affects estimation of the
H/M ratio in
123I-MIBG imaging with a low-energy (LE)
collimator [21]. Medium-energy (ME) collimators have
been shown to improve quantitative accuracy in
123I studies
[14, 21, 22]. While these results would suggest that semi-
quantitative cardiac
123I-MIBG imaging might best be
performed using ME collimators, there are practical
limitations to such a recommendation. Almost all nuclear
cardiology procedures are now performed on a multi-head
gamma camera, and many dedicated dual-head cardiac
cameras are not supplied with ME collimators (at least for
SPECT).
The precise impact of collimator choice on the prognos-
tic value has not been evaluated yet. However, it seems
feasible that the improved accuracy of the ME collimators
will decrease the number of patients with an intermediate
risk likelihood and thereby improving the prognostic
accuracy of myocardial uptake parameters of
123I-MIBG.
It is therefore important to establish the degree to which the
collimator used affects prognostic utility of the H/M
measurement.
Rigorous and uniform analysis of cardiac
123I-MIBG
parameters minimises inter-and intra-individual variation
[15, 23]. In the analysis of the entire population, numerous
variables (LVEF, collimator type, duration of acquisition,
NYHA classification and age) contributed to the prediction
of H/M, but only two of these variables are under the
control of the imager. Furthermore, the present results
suggest that the severity of cardiac sympathetic neuronal
dysfunction also modulates the impact of acquisition
parameters on the H/M determinations. For example, in
the low-risk group (H/M >2.0), none of the parameters had
a meaningful impact on the numerical result, indicating that
preserved myocardial uptake of
123I-MIBG can be reliably
determined under widely different acquisition conditions.
By comparison, considering user-controlled variables,
assessment of high-risk subjects (H/M <1.4) was affected
by delay after injection, while the assessment of H/M in the
intermediate risk subjects was affected by the collimator
employed. Standardisation therefore is most important in
assessing patients with more severe disease, although in the
present study the procedural variables only contributed a
relatively small fraction of the overall variability in H/M
determinations.
Aging is associated with changes in the cardiovascular
autonomic regulation, both under resting and stimulated
conditions. At rest, elderly subjects show increased sympa-
thetic and decreased parasympathetic activity as well as
impaired arterial baroreflex function [24–34]. The negative
correlation, although weak, between age and late H/M is in
line with the finding that sympathetic activity increases with
age typically reflected by increased circulating catechol-
amine levels, and that it is associated with decreased
myocardial uptake of
123I-MIBG, an observation previously
reported by Somsen et al. [35]a n dE s t o r c he ta l[ 36].
123I-MIBG has been shown by individual centres to have
both good reproducibility and acceptable variability, and to
have prognostic value in CHF patients [3–11, 23, 37, 38].
These single-centre experiences, however, do not necessarily
allow for extrapolation of the obtained results to other centres.
In spite of this, quantitative thresholds are often implemented
without inter-institutional validation. Because there are differ-
ences between centres in hardware, acquisition parameters
and post-acquisition processing, the extrapolation to other
centres,orgeneralisationofthesesingle-centre findings,isnot
Table 4 Multivariate analysis of clinical and acquisition related
parameters as predictors of late H/M for subjects with a late H/M 1.4–
2.0 (N=143)
Variables Coefficient b Standard error bP value
Constant 1.370 0.078
LVEF 0.004 0.001 0.001
Collimator type 0.086 0.030 0.005
Goodness-of-fit of the model: adjusted R
2 =0.100; P value=0.001
Table 5 Multivariate analysis of clinical and acquisition related
parameters as predictors of late H/M for subjects with a late H/M >2.0
(N=96)
Variables Coefficient b Standard error b P value
Constant 0.022 1.376
Duration of
acquisition
0.119 0.057 0.040
Goodness-of-fit of the model: adjusted R
2 =0.013; P value=0.347
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sets, validation in each separate centre and between centres
has not been possible.
Recently, a realistic 3D-gated cardiac phantom, the
Amsterdam gated cardiac phantom (AGATE phantom),
was developed and validated [39]. Such a phantom could
be used as a tool for the validation in each separate centre
and for standardisation between centres. However, a
phantom can only partially simulate patient characteristics.
Therefore, the phantom results obtained will give only an
impression of repeatability and variability, but they do not
necessarily reflect the accuracy of measurements in
patients. Therefore, in addition to the phantom measure-
ments, a set of reference patient studies should also be
included in a validation of the technique [40]. Moreover,
the results should be validated in each separate centre and
monitored for reproducibility and consistency.
Several medications used to treat patients with heart
failure may influence myocardial
123I-MIBG uptake.
However, in our study the data on medication use were
relatively complete, available for about 80% of the study
subjects, so any further analysis could only be based on this
subset. The problem with pursuing a medication analysis is
that any effect on
123I-MIBG uptake is related to individual
physiology and efficacy of treatment rather than on the
technicalattributes of the imaging, which was the main focus
of this manuscript. In addition, the main manuscript already
included results examining these effects, specifically that
subjects that had events were less likely to be on β-blockers
than those who did not have events [15]. A specific analysis
of the effect of medication was not deemed appropriate to
this manuscript. In addition, the use of medication that
interferes with myocardial uptake of
123I-MIBG (such as
tricyclic antidepressants), was not significant and did not
warrant a separate analysis.
The primary limitation of the present study has already
been noted, namely, that the largest influence on the H/M is
cardiac disease status rather than image acquisition param-
eters. Although collimation and acquisition duration were
independent predictors of late H/M, their individual con-
tributions to measurement variance were <10% each.
Because of the retrospective nature of this multi-centre
study, it was not possible to control for the effects of
numerous variables that might have had undetected impact
on late H/M. Studies using phantoms have already
established the effect of collimator selection on H/M, and
similar studies could be performed to examine the influence
of count rate and total counts. Additional patient studies
that included multiple acquisitions of different durations
and times post-injection could establish the effect of these
parameters on H/M with greater clarity.
In conclusion, the limited standardisation in acquisition
parameters reported in literature was also reflected in the
results of this multi-centre study. A wide variety of
collimators, delay after injection of
123I-MIBG to the start
of the acquisition and acquisition durations were reported.
In general, validation and standardisation require commit-
ment and perseverance. Moreover, without proper valida-
tion and standardisation, the role myocardial
123I-MIBG in
the clinical management of CHF will continue to be
constrained. Without these requirements, the use of myo-
cardial
123I-MIBG will be limited to a single centre research
tool for understanding the physiology of myocardial
sympathetic neuronal activity under different conditions
and after interventions. With application of appropriate
standardisation, myocardial
123I-MIBG imaging could
become a routine procedure for evaluation of heart failure
and other cardiac disease populations.
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